中集安瑞科(03899.HK)1月氫能新簽訂單按年大增逾1.3倍
中集安瑞科(03899.HK)宣布,今年1月份氫能業務新簽訂單按年增長逾1.3倍。根據中國汽車工業協會公布,今年1月國內氫燃料電池車的產量為300輛,按年增長逾3.6倍。至於銷量則按年增長近1.47倍,數量達400輛。
集團提到各種利好政策頻繁出台均有利氫能行業增長,包括山東省發布《關於對氫能車暫免收取高速公路通行費的通知》,試行免收已安裝ETC套裝設備氫能車輛的高速公路通行費,計劃為期兩年。另外,內蒙古自治區亦提出允許在化工園區外建設可再生能源電解水制氫項目和制氫加氫站。(js/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.